Currently approved drugs that target the inflammation associated with multiple sclerosis are all given by injection.
Laquinimod works by binding to receptors or immune cells. The study is published in the latest edition of 'The Lancet.'
Currently approved drugs that target the inflammation associated with multiple sclerosis are all given by injection.
Laquinimod works by binding to receptors or immune cells. The study is published in the latest edition of 'The Lancet.'